Two stocks in Healthcare
AbbVie vs Vertex Pharmaceuticals: profit, growth, debt and price compared
AbbVie and Vertex Pharmaceuticals are each stronger on 2 of 5 figures: AbbVie on price for its expected profit and price trend; Vertex Pharmaceuticals on profit margin and sales growth.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AbbVieABBV | Vertex PharmaceuticalsVRTX | |
|---|---|---|
| Net margin | 15.7% | Stronger: 30.7% |
| Revenue growth, past year | +10.32% | Stronger: +11.85% |
| Debt to equity | — | 31.0% |
| Forward P/E | Stronger: 17.6× | 26.9× |
| Dividend yield | 2.42% | — |
| Analysts | Buy · 26 | Buy · 28 |
| From its 200-day average | Stronger: +15.5% | +8.8% |
Share price over the past year
- AbbVie+22.3%
- Vertex Pharmaceuticals+23.2%
18 Nov 202518 Nov 2026
AbbVie or Vertex Pharmaceuticals: which is stronger?
- VRTX
Which is more profitable?
Vertex Pharmaceuticals keeps more of each sale as profit: 30.7% against 15.7%.
- VRTX
Which is growing its sales faster?
Vertex Pharmaceuticals is growing its sales faster: +11.85% over the past year, against +10.32%.
- ABBV
Which costs less for the profit it is expected to make?
AbbVie costs less for the profit it is expected to make: 17.6× its forward earnings, against 26.9×.
Which pays more in dividends?
AbbVie pays 2.42% a year in dividends for what a share costs, where Vertex Pharmaceuticals pays none.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- ABBV
Which is in the stronger price trend?
AbbVie's price is in the stronger trend: 15.5% above its 200-day average, against 8.8% above.
What each company does
ABBVAbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Reports results on 3 February 2027
VRTXVertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Reports results on 11 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.